HUP0400800A2 - Helyettesített 5,6,6a,11b-tetrahidro-7-oxa-5-aza-benzo[c]fluorén-6-karbonsav-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények - Google Patents
Helyettesített 5,6,6a,11b-tetrahidro-7-oxa-5-aza-benzo[c]fluorén-6-karbonsav-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0400800A2 HUP0400800A2 HU0400800A HUP0400800A HUP0400800A2 HU P0400800 A2 HUP0400800 A2 HU P0400800A2 HU 0400800 A HU0400800 A HU 0400800A HU P0400800 A HUP0400800 A HU P0400800A HU P0400800 A2 HUP0400800 A2 HU P0400800A2
- Authority
- HU
- Hungary
- Prior art keywords
- optionally substituted
- alkynyl
- alkenyl
- substituted alkyl
- heteroaryl
- Prior art date
Links
- LKAAULIYOFZTPR-UHFFFAOYSA-N 5,6,6a,11b-tetrahydro-[1]benzofuro[2,3-c]quinoline-6-carboxylic acid Chemical class C1=CC=C2C3C4=CC=CC=C4NC(C(=O)O)C3OC2=C1 LKAAULIYOFZTPR-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 7
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 3
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
Abstract
A találmány(I) általános képletű helyettesített 5,6,6a,11b-tetrahidro-7-oxa-5-aza-benzo[c]fluorén-6-karbonsav-származékokra, e vegyületekelőállítására, a fenti vegyületeket tartalmazó gyógyszerekre és evegyületeknek bizonyos indikációkban - különösen fájdalom kezelésére -történő felhasználására vonatkozik. A képletben R1 R2, R3 és R4jelentése egymástól függetlenül H, F, Cl, Br, I, CN, NO2; adottesetben helyettesített alkil-, alkinil- vagy alkinil-csoport; adottesetben helyettesített cikloalkilcsoport; illetve egy megfelelőheterociklus; adott esetben helyettesített alkil-aril- vagy alkil-heteroaril-csoport; adott esetben helyettesített aril- vagyheteroaril-csoport; ORI1, OC(O)Rl1, C(O)R11,C(O)ORI1,C(O)NR11R11,NR11R11, S(O2)R11vagy SR11; R5 jelentése hidrogénatom;adott esetben helyettesített alkil-, alkenil- vagy alkinil-csoport;adott esetben helyettesített cikloalkil-csoport; illetve egy megfelelőheterociklus; adott esetben helyettesített alkil-aril- vagy alkil-heteroaril-csoport; adott esetben helyettesített aril- vagyheteroaril-csoport; R6 jelentése R12 vagy ZR12; ahol Z jelentése adottesetben helyettesített alkil-, alkenil- vagy alkinilcsoport; és R12jelentése hidrogénatom; adott esetben helyettesített alkil-, alkenil-vagy alkinilcsoport; adott esetben helyettesített cikloalkil-csoport;illetve egy megfelelő heterociklus; adott esetben helyettesített aril-vagy heteroaril-csoport; C(O)R13, C(O)OR13, C(S)R13, C(S)OR13, illetveS(O)2R13 SR14; ahol R14 jelentése adott esetben helyettesített aril-vagy heteroaril-csoport, C(O)N15R16 ,C(O)NR15NR16R17 ,C(NR15)NR16R17,C(S)NR15R16 vagy C(S)NR15NR16R17 R7 R8 R9és Rl0 jelentése egymástólfüg getlenül H, F, Cl, Br, I, CN, NO2; adott esetben helyettesítettalkil-, alkenil- vagy alkinil-csoport; OR18, OC(O)R18, OC(S)R18,C(O)R18, C(O)OR18, C(S)R18, C(S)OR18, SR18, S(O)R18 vagy Si(O2)R18;NR19R20,NR19C(O)R20,C(NR19)NR2oR21, NR19C(S)R20, C(S)NR19R20 vagyC(S)NR19NR20R21 vagy S(02)NR19R20; vagy R7 és R8 ,R8 és R9 vagy R9 ésRl0 együtt =CR22-CH=CH-CH= vagy CH-CR22=CH-CH= csoportot képez; aholR22 jelentése H, F, Cl, Br, I, OH vagy adott esetben helyettesítettalkil-, alkenil- vagy alkinilcsoport. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10137487A DE10137487A1 (de) | 2001-08-03 | 2001-08-03 | Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate |
| PCT/EP2002/008886 WO2003014124A1 (de) | 2001-08-03 | 2002-08-05 | SUBSTITUIERTE 5,6,6a,11b-TETRAHYDRO-7-OXA-5-AZA-BENZO'C!FLUOREN-6-CARBONSÄUREDERIVATE ALS NMDA-ANTAGONISTEN |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0400800A2 true HUP0400800A2 (hu) | 2004-07-28 |
| HUP0400800A3 HUP0400800A3 (en) | 2007-09-28 |
Family
ID=7693857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0400800A HUP0400800A3 (en) | 2001-08-03 | 2002-08-05 | Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives, process for their preparation, their use and pharmaceutical compositions containing them |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7199130B2 (hu) |
| EP (1) | EP1412361B1 (hu) |
| JP (1) | JP2005500374A (hu) |
| KR (1) | KR20040020078A (hu) |
| CN (1) | CN1697836A (hu) |
| AT (1) | ATE402178T1 (hu) |
| BR (1) | BR0211734A (hu) |
| CA (1) | CA2456124A1 (hu) |
| CO (1) | CO5550438A2 (hu) |
| DE (2) | DE10137487A1 (hu) |
| EC (1) | ECSP044968A (hu) |
| ES (1) | ES2310211T3 (hu) |
| HU (1) | HUP0400800A3 (hu) |
| IL (1) | IL160160A0 (hu) |
| MX (1) | MXPA04000953A (hu) |
| NO (1) | NO20040471L (hu) |
| NZ (1) | NZ531372A (hu) |
| PL (1) | PL368073A1 (hu) |
| RU (1) | RU2004106533A (hu) |
| WO (1) | WO2003014124A1 (hu) |
| ZA (1) | ZA200401725B (hu) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10304950A1 (de) * | 2003-02-06 | 2004-08-19 | Grünenthal GmbH | Herstellung von Tetrahydrochinolinbenzofuranen |
| KR20050021629A (ko) * | 2003-08-25 | 2005-03-07 | 학교법인 이화학당 | 신규한 벤조플루오렌 디온계 화합물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69029668T2 (de) * | 1989-03-08 | 1997-08-07 | Merck Sharp & Dohme | Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten |
| DE19536809A1 (de) * | 1995-10-02 | 1997-04-03 | Basf Ag | Heterocyclisch substituierte Salicylsäurederivate |
| US5925527A (en) * | 1997-02-04 | 1999-07-20 | Trega Biosciences, Inc. | Tricyclic Tetrahydroquinoline derivatives and tricyclic tetrahydroquinoline combinatorial libraries |
| GB9706294D0 (en) * | 1997-03-26 | 1997-05-14 | Glaxo Wellcome Spa | Heterocyclic compound |
| MY125037A (en) * | 1998-06-10 | 2006-07-31 | Glaxo Wellcome Spa | 1,2,3,4 tetrahydroquinoline derivatives |
| DE10005302A1 (de) * | 2000-02-07 | 2002-01-17 | Gruenenthal Gmbh | Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate |
-
2001
- 2001-08-03 DE DE10137487A patent/DE10137487A1/de not_active Withdrawn
-
2002
- 2002-08-05 CA CA002456124A patent/CA2456124A1/en not_active Abandoned
- 2002-08-05 BR BR0211734-7A patent/BR0211734A/pt not_active IP Right Cessation
- 2002-08-05 NZ NZ531372A patent/NZ531372A/en unknown
- 2002-08-05 WO PCT/EP2002/008886 patent/WO2003014124A1/de active IP Right Grant
- 2002-08-05 CN CNA028195124A patent/CN1697836A/zh active Pending
- 2002-08-05 IL IL16016002A patent/IL160160A0/xx unknown
- 2002-08-05 PL PL02368073A patent/PL368073A1/xx not_active Application Discontinuation
- 2002-08-05 DE DE50212538T patent/DE50212538D1/de not_active Expired - Lifetime
- 2002-08-05 JP JP2003519073A patent/JP2005500374A/ja not_active Withdrawn
- 2002-08-05 MX MXPA04000953A patent/MXPA04000953A/es unknown
- 2002-08-05 HU HU0400800A patent/HUP0400800A3/hu unknown
- 2002-08-05 RU RU2004106533/04A patent/RU2004106533A/ru not_active Application Discontinuation
- 2002-08-05 AT AT02764838T patent/ATE402178T1/de active
- 2002-08-05 EP EP02764838A patent/EP1412361B1/de not_active Expired - Lifetime
- 2002-08-05 ES ES02764838T patent/ES2310211T3/es not_active Expired - Lifetime
- 2002-08-05 KR KR10-2004-7001698A patent/KR20040020078A/ko not_active Application Discontinuation
-
2004
- 2004-02-02 NO NO20040471A patent/NO20040471L/no not_active Application Discontinuation
- 2004-02-02 EC EC2004004968A patent/ECSP044968A/es unknown
- 2004-02-03 US US10/770,126 patent/US7199130B2/en not_active Expired - Fee Related
- 2004-02-03 CO CO04008285A patent/CO5550438A2/es not_active Application Discontinuation
- 2004-03-02 ZA ZA200401725A patent/ZA200401725B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04000953A (es) | 2004-04-20 |
| NZ531372A (en) | 2005-03-24 |
| HUP0400800A3 (en) | 2007-09-28 |
| EP1412361A1 (de) | 2004-04-28 |
| CO5550438A2 (es) | 2005-08-31 |
| ATE402178T1 (de) | 2008-08-15 |
| DE10137487A1 (de) | 2003-03-27 |
| CA2456124A1 (en) | 2003-02-20 |
| ECSP044968A (es) | 2004-03-23 |
| CN1697836A (zh) | 2005-11-16 |
| KR20040020078A (ko) | 2004-03-06 |
| ES2310211T3 (es) | 2009-01-01 |
| PL368073A1 (en) | 2005-03-21 |
| US7199130B2 (en) | 2007-04-03 |
| DE50212538D1 (de) | 2008-09-04 |
| RU2004106533A (ru) | 2005-07-27 |
| EP1412361B1 (de) | 2008-07-23 |
| ZA200401725B (en) | 2005-01-31 |
| JP2005500374A (ja) | 2005-01-06 |
| IL160160A0 (en) | 2004-07-25 |
| BR0211734A (pt) | 2004-09-21 |
| WO2003014124A1 (de) | 2003-02-20 |
| US20040248889A1 (en) | 2004-12-09 |
| NO20040471L (no) | 2004-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0400888A2 (hu) | Helyettesített ciklohexán-1,4-diamin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0401339A2 (hu) | Új 4-anilino-3-kinolinkarboxamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| NO20060324L (no) | [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni | |
| SE0104140D0 (sv) | Novel Compounds | |
| HUP0402640A2 (hu) | Indolilalkilamin-származékok 5-hidroxitriptamin-6 ligandumokként, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0302480A2 (hu) | Piridinonszármazékok ateroszklerózis kezelésére, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0302380A2 (hu) | Cisztein-proteázok reverzibilis inhibitoraiként alkalmazható új spiroheterociklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| NO20074657L (no) | Nitrogenholdige aromatiske ringforbindelser | |
| HUP0400810A2 (hu) | Helyettesített 1-oxa-2,8-diaza-spiro[4.5]dec-2-én-származékok, eljárás előállításukra, alkalmazásuk, és az ezeket tartalmazó gyógyszerkészítmények | |
| NO20062193L (no) | Bisykliske [3.1.0] derivater som glysintransportorinhibitorer | |
| SE0102438D0 (sv) | New compounds | |
| HUP0102425A2 (hu) | Gyomorsav-elválasztást gátló imidazo-piridin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| SE9904738D0 (sv) | Novel compounds | |
| HUP0102084A2 (hu) | Kinolinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0300846A2 (hu) | Imidazopirimidin- és triazolopirimidin-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyszerkészítmények | |
| DE602005012811D1 (de) | Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd | |
| NO20063132L (no) | Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer | |
| HUP0400682A2 (hu) | 5-Hidroxitriptamin-6-ligandumként használható heterociklilalkilindol- és -azaindol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| DE50310161D1 (de) | Kationisch substituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung | |
| SE9902765D0 (sv) | Novel compounds | |
| DE60201259D1 (de) | Chemische verbindungen | |
| HUP0104224A2 (hu) | Szubsztituált kaprolaktámok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk tumorok kezelésére | |
| HU9201290D0 (en) | 1-/pirido/3,4-b/-1,4-oxazinyl-4-yl/-1h-indole derivatives, process for their production and for the production of medical preparations containing them as active agents | |
| ATE66913T1 (de) | Amidverbindungen, verfahren zu ihrer herstellung und zusammensetzung zur aktivierung gastromotorischer funktionen. | |
| SE9902551D0 (sv) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |